These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 10980998)

  • 21. What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: viral dynamics, viral levels at certain time points, or a combination of both?
    Weiland O
    J Hepatol; 2009 Jul; 51(1):4-7. PubMed ID: 19446915
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment options for nonresponders and relapsers to initial therapy for hepatitis C.
    Duncan M; Younossi Z
    Cleve Clin J Med; 2003 Sep; 70 Suppl 4():S21-6. PubMed ID: 14558642
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reinforced interferon alpha-2b and ribavirin is more effective than standard combination therapy in the retreatment of chronic hepatitis C previously nonresponsive to interferon: a randomized trial.
    Poynard T; Marcellin P; Bissery A; Myers RP; Moussalli J; Degos F; Dhumeaux D; Riachi G; Bronowicki JP; Brissot P; Buffet C; Serfaty L; Naveau S; Sogni P; Beaugrand M; Gayno S; Larrey D; Samuel D; Eugene C; Pol S; Bedossa P; Daurat V; Chaumet-Riffaud P;
    J Viral Hepat; 2003 May; 10(3):197-204. PubMed ID: 12753338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence.
    Bizollon T; Ahmed SN; Radenne S; Chevallier M; Chevallier P; Parvaz P; Guichard S; Ducerf C; Baulieux J; Zoulim F; Trepo C
    Gut; 2003 Feb; 52(2):283-7. PubMed ID: 12524414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term pegylated interferon monotherapy following 72 weeks of pegylated interferon and ribavirin in hepatitis C virus genotype-1-infected slow responders.
    Watanabe S; Kobayashi Y; Kawata K; Noritake H; Chida T; Nagasawa M; Kageyama F; Kawamura K; Sasada Y; Suda T
    Intern Med; 2015; 54(3):273-9. PubMed ID: 25748735
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alfa-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) in retreatment of chronic hepatitis C patients, nonresponders and relapsers to previous conventional interferon plus ribavirin therapy.
    Parise E; Cheinquer H; Crespo D; Meirelles A; Martinelli A; Sette H; Gallizi J; Silva R; Lacet C; Correa E; Cotrim H; Fonseca J; Paraná R; Spinelli V; Amorim W; Tatsch F; Pessoa M;
    Braz J Infect Dis; 2006 Feb; 10(1):11-6. PubMed ID: 16767309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationships between hepatic iron content and virologic response in chronic hepatitis C patients treated with interferon and ribavirin.
    Rulyak SJ; Eng SC; Patel K; McHutchison JG; Gordon SC; Kowdley KV
    Am J Gastroenterol; 2005 Feb; 100(2):332-7. PubMed ID: 15667490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C. The International Hepatitis Interventional Therapy Group.
    McHutchison JG; Poynard T; Pianko S; Gordon SC; Reid AE; Dienstag J; Morgan T; Yao R; Albrecht J
    Gastroenterology; 2000 Nov; 119(5):1317-23. PubMed ID: 11054390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group.
    Davis GL; Esteban-Mur R; Rustgi V; Hoefs J; Gordon SC; Trepo C; Shiffman ML; Zeuzem S; Craxi A; Ling MH; Albrecht J
    N Engl J Med; 1998 Nov; 339(21):1493-9. PubMed ID: 9819447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon.
    Ferreira Sda C; Carneiro Mde V; Souza FF; Teixeira AC; Villanova MG; Figueiredo JF; Passos AD; Ramalho LN; Zucoloto S; Martinelli Ade L
    Braz J Infect Dis; 2010; 14(4):330-4. PubMed ID: 20963315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sustained response to interferon-ribavirin combination therapy predicted by a model of hepatitis C virus dynamics using both HCV RNA and alanine aminotransferase.
    Colombatto P; Civitano L; Oliveri F; Coco B; Ciccorossi P; Flichman D; Campa M; Bonino F; Brunetto MR
    Antivir Ther; 2003 Dec; 8(6):519-30. PubMed ID: 14760885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C.
    Myers RP; Poynard T
    Cochrane Database Syst Rev; 2002; (4):CD003617. PubMed ID: 12519606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C.
    Chan HL; Ren H; Chow WC; Wee T;
    Hepatology; 2007 Aug; 46(2):315-23. PubMed ID: 17654600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferon alfa-2b plus ribavirin for chronic hepatitis C patients who have not responded to interferon monotherapy.
    Lo Iacono O; Castro A; Diago M; Moreno JA; Fernandez-Bermejo M; Vega P; García V; Carbonell P; Sanz P; Borque MJ; García-Buey L; García-Monzón C; Pedreira J; Moreno-Otero R
    Aliment Pharmacol Ther; 2000 Apr; 14(4):463-9. PubMed ID: 10759626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Available options for treatment of interferon nonresponders.
    Bacon BR
    Am J Med; 1999 Dec; 107(6B):67S-70S. PubMed ID: 10653461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature].
    Wedemeyer H; Jäckel E; Wedemeyer J; Frank H; Schüler A; Trautwein C; Manns MP
    Z Gastroenterol; 1998 Sep; 36(9):819-27. PubMed ID: 9795411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chronic hepatitis C: management of treatment failures.
    Keeffe EB
    Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S102-5. PubMed ID: 16234055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.